《大行報告》匯豐研究降歐舒丹(00973.HK)評級至「持有」 目標價下調至25元
匯豐研究發表評級報告指,歐舒丹(00973.HK)旗下品牌Elemis和Sol de Janeiro近日對集團投資組合作出非常強勁的補充,併產生非常強勁的收入增長和穩定的營業利潤;該行指,集團基礎息稅前利潤率實際上較預期好,但受到俄羅斯業務關閉及其他因素等減值,令其表現最終低於預期。
該行指,由於集團冀望在2024財年再次加大投資,提出息稅前利潤率達12%的指引,令該行將息稅前利潤預測下調17%,盈利預測則下調19%。該行將其目標價由32元下調至25元,其評級則降至「持有」。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.